Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AAA Ramps Up Lutathera Launch And Plans Expansion Under Novartis Ownership

Executive Summary

Advanced Accelerator Applications is ramping up the launch of the first-in-class peptide receptor radionuclide therapy (PRRT), but Novartis has much broader ambitions for the radiopharmaceutical platform. AAA President Susanne Schaffert talked to Scrip about the growth strategy.

You may also be interested in...



Novartis Lays A New Foundation In Prostate Cancer With Second Radioligand Launch

"We have big plans," oncology president Susanne Schaffert said in an interview about launching Pluvicto, its new radioligand therapy for prostate cancer.

Lead From The Front – But Resist Micromanaging

Theragnostics’ CEO Greg Mullen aims to use his wide-ranging “hands-on” scientific and commercial experience to help clinch a $45m series A financing round that will fund a Phase I/II basket study to develop the biotech’s lead radiotherapeutic PARP inhibitor.

Theragnostics Ltd: Developing New Radiotherapies Targeted To PARP

Emerging Company Profile: The transatlantic radiopharmaceuticals start-up Theragnostics Ltd. is developing radiotherapeutics and radiodiagnostics for prostate and other cancers.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC123355

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel